aberrations and match enough to tolerate FCR therapy, should be superior candidates for the latter, Together with the advantage currently being this cure can be finished in six months even though ibrutinib need to be taken indefinitely.It is necessary to look at the flow cytometry histograms to ascertain the depth of expression and whether or not t